<DOC>
	<DOCNO>NCT01605981</DOCNO>
	<brief_summary>This open label , non randomize , prospective , multicenter , phase II clinical trial evaluate nilotinib 400 mg BID treatment newly diagnose CML-AP patient . Patients enrol study receive 400mg nilotinib , orally , twice daily ( 800mg/day )</brief_summary>
	<brief_title>Trial Evaluating Nilotinib Treatment Newly Diagnosed CML Patients Accelerated Phase .</brief_title>
	<detailed_description>Patients evaluate safety throughout study response every month first 3 month , every 3 month thereafter month 24 . BCR-ABL transcripts measurement QRT-PCR mutation analyse do peripheral blood sample cytogenetic analysis bone marrow aspirate . Laboratory test ( hematology , blood chemistry ) , ECG physical examination do every visit . Drug pharmacokinetics assess study . For screen Baseline period , see chart attach</detailed_description>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Male female patient age &gt; 18 year old ; Diagnosis Chronic Myeloid leukemia Accelerated Phase ( CMLAP ) ; Patients CMLAP ( See Appendix 1 ) within 3 month diagnosis ( date initial diagnosis date first report cytogenetic analysis ) . Standard conventional cytogenetic analysis must do bone marrow . FISH use purpose inclusion ; Patients atypical BCRABL transcript eligible ( transcript b2a2 b3a2 ) ; No previous treatment antileukemic drug exception hydroxyurea ( HU ) and/or anagrelide . In emergent case patient require disease management await study start , commercial supply Gleevec/Glivec dose may prescribe patient longer 2 week duration ; ECOG 0,1 2 ; Normal serum level &gt; LLN ( low limit normal ) correct within normal limit supplement , prior first dose study medication , potassium magnesium calcium ; AST ALT &lt; 2.5 x ULN ( upper limit normal ) &lt; 5.0 x ULN consider due leukemia ; Alkaline phosphatase &lt; 2.5 x ULN , unless consider due leukemia ; Total bilirubin &lt; 1.5 x ULN ; Serum lipase amylase &lt; 1.5 x ULN ; Written inform consent prior study procedure perform . Patients Chronic Blastic Phases . Patients consider Ph negative confirm cytogenetic diagnosis Philadelphia Ph+ chromosome ( 9 ; 22 translocation ) &gt; 20 metaphase . Treatment tyrosine kinase inhibitor antileukemic agent treatment ( include HSCT ) longer 2 week , exception HU and/or anagrelide Previously document T315I mutation ; Uncontrolled congestive heart failure hypertension ; Myocardial infarction unstable angina pectoris within past 12 month ; Significant arrhythmia , include history presence clinically significant ventricular atrial tachyarrhythmias , clinically significant bradycardia , long QT syndrome and/or QTc &gt; 450 msec screen ECG ( use QTcF formula ) . Patients complete LBBB ; History confirm acute chronic pancreatitis ; Other concurrent uncontrolled medical condition ( e.g . uncontrolled diabetes , active uncontrolled infection , acute chronic liver renal disease ) could cause unacceptable safety risk compromise compliance protocol ; Impaired gastrointestinal function GI disease may alter absorption study drug ( e.g . ulcerative disease , uncontrolled nausea , vomit diarrhea , malabsorption syndrome , small bowel resection gastric bypass surgery ) ; Patients another primary malignancy currently clinically significant require active intervention ; Concomitant medication potential QT prolongation ( See link complete list : http : //www.torsades.org/medicalpros/druglists/printabledruglist.cfm ) ; Concomitant medication know interact CYP450 isoenzymes ( CYP 3A4 , CYP2C9 , CYP2C8 , ( See link complete list ( http : //medicine.iupui.edu/flockhart/table.htm ) ; History significant congenital acquire bleed disorder unrelated cancer ; Patients undergone major surgery â‰¤ 2 week prior start study drug recover side effect therapy ; Patients pregnant breastfeed adult reproductive potential employ effective method birth control . ( Women childbearing potential must negative serum pregnancy test within 48 hrs prior administration nilotinib ) . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female patient must agree employ effective barrier method birth control throughout entire study 3 month follow discontinuation study drug ; Treatment hematopoietic colonystimulating growth factor ( e.g . GCSF , GMCSF ) 1 week prior start study drug ; Treatment investigational agent ( define use accordance approve indication ) within 30 day Day 1 ; Patients unwilling unable comply protocol . Note : Patients meet one inclusion exclusion criterion may rescreened study later time medical condition transient appropriately treat ( provide enter study within 3 month diagnosis ) . Date diagnosis define date confirmatory bone marrow cytogenetic analysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Nilotinib</keyword>
	<keyword>CML patient</keyword>
	<keyword>accelerate phase</keyword>
</DOC>